Charles River Laboratories International, Inc.CRLNYSE
Loading
EPS Growth Under PressureDecelerating
Percentile Rank0
Year-over-Year Change
Year-over-year earnings per share growth rate
Percentile
P0
Near historical low
vs 5Y Ago
-15.5x
Contraction
Streak
2 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -606.31% |
| Q3 2025 | 4.72% |
| Q2 2025 | 112.00% |
| Q1 2025 | 111.85% |
| Q4 2024 | -414.93% |
| Q3 2024 | -23.43% |
| Q2 2024 | 33.59% |
| Q1 2024 | -64.11% |
| Q4 2023 | 114.71% |
| Q3 2023 | -10.05% |
| Q3 2023 | -5.97% |
| Q2 2023 | -45.38% |
| Q4 2022 | 93.68% |
| Q3 2022 | -11.63% |
| Q2 2022 | 16.85% |
| Q1 2022 | -32.60% |
| Q4 2021 | 33.17% |
| Q3 2021 | 16.48% |
| Q2 2021 | 43.09% |
| Q1 2021 | -57.29% |
| Q4 2020 | 39.13% |
| Q3 2020 | 52.21% |
| Q2 2020 | 32.04% |
| Q1 2020 | -37.20% |
| Q4 2019 | 10.07% |
| Q3 2019 | 65.56% |
| Q2 2019 | -21.05% |
| Q1 2019 | -8.06% |
| Q4 2018 | -0.80% |
| Q3 2018 | 12.61% |
| Q2 2018 | 0.91% |
| Q1 2018 | 271.88% |
| Q4 2017 | -157.66% |
| Q3 2017 | -1.77% |
| Q3 2017 | 15.31% |
| Q2 2017 | 3.16% |
| Q4 2016 | 18.75% |
| Q3 2016 | 6.67% |
| Q2 2016 | -6.25% |
| Q1 2016 | 15.94% |